Table 2B.
Incidence Rates per 100 Person-Years of Chlamydia, Gonorrhea, and Syphilisa by Baseline Demographic Characteristicsb Among DC Cohort Participants (n = 6762), Stratified for Race/Ethnicity by Age, Gender, and Risk Behavior
| No. | Chlamydia | Gonorrhea | Syphilis | Any STI | ||
|---|---|---|---|---|---|---|
| Rate (95% CI) | Rate (95% CI) | Rate (95% CI) | Rate (95% CI) | |||
| Stratify race/ethnicity by age, y | ||||||
| Non-Hispanic black | 0–17 | 131 | 3.5 (2.0–6.1) | 2.6 (1.3–5.0) | 0.3 (0.0–2.0) | 5.8 (3.7–8.9) |
| 18–34 | 1057 | 5.7 (4.8–6.7) | 4.9 (4.1–5.9) | 1.5 (1.1–2.1) | 10.8 (9.6–12.2) | |
| 35–54 | 2732 | 0.9 (0.7–1.2) | 0.7 (0.5–0.9) | 0.6 (0.4–0.8) | 2.0 (1.7–2.4) | |
| 55+ | 1238 | 0.1 (0.0–0.3) | 0.2 (0.1–0.4) | 0.1 (0.0–0.2) | 0.3 (0.2–0.6) | |
| Non-Hispanic white | 0–17 | 8 | NA | NA | NA | NA |
| 18–34 | 141 | 7.8 (5.5–11.2) | 7.3 (5.1–10.6) | 1.6 (0.7–3.5) | 13.1 (9.9–17.2) | |
| 35–54 | 537 | 2.2 (1.6–3.0) | 2.4 (1.7–3.3) | 1.4 (1.0–2.2) | 5.3 (4.3–6.6) | |
| 55+ | 254 | 0.6 (0.3–1.5) | 0.9 (0.4–1.8) | 0.5 (0.2–1.3) | 1.9 (1.1–3.1) | |
| Hispanic | 0–17 | 5 | NA | NA | NA | NA |
| 18–34 | 89 | 6.7 (3.8–11.8) | 7.2 (4.2–12.5) | 1.1 (0.3–4.5) | 13.4 (9.0–20.0) | |
| 35–54 | 170 | 4.0 (2.5–6.6) | 4.3 (2.7–6.9) | 2.5 (1.4–4.7) | 9.4 (6.8–13.0) | |
| 55+ | 48 | NA | NA | 1.1 (0.2–8.1) | 1.1 (0.2–8.1) | |
| Stratify race/ethnicity by gender | ||||||
| Non-Hispanic black | Male | 3414 | 1.9 (1.7–2.2) | 1.8 (1.5–2.1) | 0.9 (0.7–1.1) | 4.1 (3.7–4.5) |
| Female | 1648 | 0.8 (0.6–1.1) | 0.4 (0.2–0.6) | 0.1 (0.0–0.2) | 1.2 (0.9–1.6) | |
| Transgender Female | 96 | 6.1 (3.7–10.0) | 3.4 (1.8–6.6) | 1.9 (0.8–4.6) | 10.7 (7.4–15.5) | |
| Non-Hispanic white | Male | 882 | 2.6 (2.1–3.3) | 2.8 (2.2–3.5) | 1.2 (0.9–1.8) | 5.7 (4.8–6.7) |
| Female | 55 | NA | NA | NA | NA | |
| Transgender Female | 3 | NA | NA | NA | NA | |
| Hispanic | Male | 270 | 4.7 (3.2–6.8) | 4.7 (3.2–6.8) | 2.2 (1.3–3.8) | 10.1 (7.8–13.0) |
| Female | 31 | NA | NA | NA | 0.0 (0.0–) | |
| Transgender Female | 11 | NA | 6.6 (1.6–26.2) | NA | 6.6 (1.6–26.2) | |
| Stratify race/ethnicity by risk behavior | ||||||
| Non-Hispanic black | MSM | 1620 | 3.8 (3.3–4.5) | 3.6 (3.1–4.2) | 1.7 (1.3–2.1) | 8.1 (7.3–8.9) |
| HRH | 1792 | 0.5 (0.3–0.8) | 0.2 (0.1–0.4) | 0.1 (0.0–0.2) | 0.8 (0.6–1.1) | |
| IDU | 425 | 0.1 (0.0–0.6) | NA | NA | 0.1 (0.0–0.6) | |
| Other | 292 | 1.9 (1.1–3.3) | 1.2 (0.6–2.4) | NA | 3.0 (2.0–4.6) | |
| Unknown | 1029 | 0.7 (0.4–1.1) | 0.4 (0.2–0.8) | 0.4 (0.2–0.7) | 1.4 (1.0–2.0) | |
| Non-Hispanic white | MSM | 667 | 3.3 (2.6–4.2) | 3.6 (2.9–4.6) | 1.6 (1.1–2.3) | 7.3 (6.2–8.6) |
| HRH | 58 | NA | NA | NA | NA | |
| IDU | 19 | NA | NA | NA | NA | |
| Other | 37 | NA | NA | NA | NA | |
| Unknown | 159 | 0.9 (0.3–2.3) | 0.2 (0.0–1.5) | 0.2 (0.0–1.5) | 1.3 (0.6–2.9) | |
| Hispanic | MSM | 194 | 4.7 (3.1–7.2) | 6.0 (4.2–8.7) | 2.4 (1.3–4.3) | 11.2 (8.5–14.7) |
| HRH | 57 | 1.0 (0.1–6.8) | NA | 1.0 (0.1–6.8) | 1.9 (0.5–7.7) | |
| IDU | 4 | NA | 18.8 (2.7–133.6) | NA | 18.8 (2.7–133.6) | |
| Other | 9 | NA | NA | NA | NA | |
| Unknown | 48 | 6.7 (2.8–16.0) | 1.3 (0.2–9.5) | 1.3 (0.2–9.5) | 9.3 (4.4–19–5) | |
| Stratify age by risk behavior | ||||||
| MSM | 5 | 24.0 (6.0–95.0) | 24.0 (6.0–95.0) | 12.0 (1.7–85.0) | 48.0 (18127.0) | |
| HRH | 8 | 16.0 (5.1–49.0) | 5.2 (0.7–37.0) | NA | 21.0 (7.9–56.0) | |
| IDU | 0 | NA | NA | NA | NA | |
| Other | 132 | 1.9 (0.9–4.1) | 1.7 (0.7–3.7) | NA | 3.3 (1.9–5.9) | |
| 0–17 y | Unknown | 4 | NA | NA | NA | NA |
| MSM | 796 | 7.7 (6.5–9.0) | 7.8 (6.7–9.2) | 2.4 (1.8–3.1) | 15.0 (14.0–17.0) | |
| HRH | 300 | 2.1 (1.3–3.4) | 1.0 (0.5–2.0) | 0.3 (0.1–1.1) | 3.0 (2.0–4.6) | |
| IDU | 5 | NA | 9.5 (1.3–67.0) | NA | 9.5 (1.3–67.0) | |
| Other | 120 | 2.2 (1.0–4.8) | 1.1 (0.3–3.3) | NA | 3.2 (1.7–6.2) | |
| 18–34 y | Unknown | 155 | 5.5 (3.5–8.8) | 1.5 (0.6–3.7) | 1.2 (0.5–3.3) | 8.0 (5.4–12.0) |
| MSM | 1433 | 2.5 (2.1–3.0) | 2.4 (1.9–2.9) | 1.8 (1.4–2.2) | 5.9 (5.2–6.7) | |
| HRH | 1200 | 0.3 (0.1–0.5) | 0.1 (0.0–0.3) | 0.1 (0.0–0.3) | 0.5 (0.3–0.8) | |
| IDU | 156 | NA | NA | NA | NA | |
| Other | 72 | 0.5 (0.1–3.8) | NA | NA | 0.5 (0.1–3.8) | |
| 35–54 y | Unknown | 772 | 0.3 (0.1–0.7) | 0.3 (0.1–0.7) | 0.3 (0.1–0.7) | 0.8 (0.5–1.4) |
| MSM | 417 | 0.5 (0.2–1.1) | 0.9 (0.5–1.7) | 0.5 (0.2–1.1) | 1.8 (1.1–2.7) | |
| HRH | 481 | NA | NA | 0.1 (0.0–0.6) | 0.1 (0.0–0.6) | |
| IDU | 291 | 0.1 (0.0–0.8) | NA | NA | 0.1 (0.0–0.8) | |
| Other | 29 | NA | NA | NA | NA | |
| 55+ y | Unknown | 381 | 0.2 (0.1–0.9) | 0.1 (0.0–0.8) | 0.1 (0.0–0.8) | 0.5 (0.2–1.2) |
| Stratify age by gender | ||||||
| Male | 61 | 3.1 (1.3–7.5) | 1.9 (0.6–5.8) | 0.6 (0.1–4.4) | 5.0 (2.5–10) | |
| Female | 88 | 3.0 (1.4–6.2) | 2.5 (1.1–5.6) | NA | 5.1 (2.9–8.9) | |
| 0–17 y | Transgender female | 0 | NA | NA | NA | NA |
| Male | 993 | 6.6 (5.6–7.7) | 6.2 (5.3–7.3) | 2.0 (1.5–2.6) | 13.0 (11–14) | |
| Female | 338 | 2.3 (1.5–3.7) | 1.2 (0.6–2.2) | NA | 3.3 (2.2–4.8) | |
| 18–34 y | Transgender female | 45 | 10 (5.7–18.0) | 9.1 (5.1–16.0) | 3.3 (1.2–8.8) | 21.0 (14.0–31.0) |
| Male | 2552 | 1.5 (1.3–1.9) | 1.5 (1.2–1.8) | 1.1 (0.9–1.4) | 3.7 (3.3–4.2) | |
| Female | 1024 | 0.3 (0.1–0.6) | 0.1 (0.0–0.3) | 0.1 (0.0–0.3) | 0.4 (0.2–0.8) | |
| 35–54 y | Transgender female | 57 | 1.8 (0.6–5.6) | 0.6 (0.1–4.3) | 0.6 (0.1–4.3) | 3.0 (1.2–7.2) |
| Male | 1217 | 0.2 (0.1–0.5) | 0.4 (0.2–0.6) | 0.2 (0.1–0.4) | 0.7 (0.5–1.1) | |
| Female | 371 | NA | NA | 0.1 (0.0–0.8) | 0.1 (0.0–0.8) | |
| 55+ y | Transgender female | 11 | 3.8 (0.5–27.0) | 0.0 (0.0–0.0) | NA | 3.8 (0.5–27) |
Abbreviations: CI, confidence interval; HRH, heterosexual; IDU, injection drug user; MSM, men who have sex with men; NA, insufficient data for calculation; STI, sexually transmitted infection.
aRate per 100 person-years of observation using Rothman/Greenland estimation for 95% confidence intervals.
bAll characteristics are at the time of consent into the DC Cohort.